The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia

Venetoclax is a promising agent in the treatment of acute myeloid leukemia, though its antileukemic activity is limited to combination therapies. Mcl-1 downregulation, Bim upregulation, and DNA damage have been identified as potential ways to enhance venetoclax activity. In this study, we combine ve...

Full description

Bibliographic Details
Main Authors: Xinyu Li, Yongwei Su, Katie Hege, Gerard Madlambayan, Holly Edwards, Tristan Knight, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jay Yang, Regan Miller, Guan Wang, Lijing Zhao, Yue Wang, Hai Lin, Jeffrey W. Taub, Yubin Ge
Format: Article
Language:English
Published: Ferrata Storti Foundation 2020-03-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/9686

Internet

https://haematologica.org/article/view/9686

Similar Items